Market Research Logo

Recurrent Malignant Glioma - Pipeline Review, H2 2015

Recurrent Malignant Glioma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Recurrent Malignant Glioma - Pipeline Review, H2 2015’, provides an overview of the Recurrent Malignant Glioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Malignant Glioma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Recurrent Malignant Glioma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Recurrent Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Recurrent Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Recurrent Malignant Glioma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Recurrent Malignant Glioma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Recurrent Malignant Glioma Overview
Therapeutics Development
Pipeline Products for Recurrent Malignant Glioma - Overview
Pipeline Products for Recurrent Malignant Glioma - Comparative Analysis
Recurrent Malignant Glioma - Therapeutics under Development by Companies
Recurrent Malignant Glioma - Therapeutics under Investigation by Universities/Institutes
Recurrent Malignant Glioma - Pipeline Products Glance
Clinical Stage Products
Recurrent Malignant Glioma - Products under Development by Companies
Recurrent Malignant Glioma - Products under Investigation by Universities/Institutes
Recurrent Malignant Glioma - Companies Involved in Therapeutics Development
Amgen Inc.
AstraZeneca Plc
Eisai Co., Ltd.
MediGene AG
Tiziana Life Sciences Plc
ZIOPHARM Oncology, Inc.
Recurrent Malignant Glioma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Ad-RTS-IL-12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboxyamidotriazole Orotate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Refractory Gliomas - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target IL-13 for Malignant Glioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Recurrent Malignant Glioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
disufenton sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DNX-2401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
irofulven - Drug Profile
Product Description
Mechanism of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rilotumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recurrent Malignant Glioma - Recent Pipeline Updates
Recurrent Malignant Glioma - Dormant Projects
Recurrent Malignant Glioma - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Recurrent Malignant Glioma, H2 2015
Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Recurrent Malignant Glioma - Pipeline by Amgen Inc., H2 2015
Recurrent Malignant Glioma - Pipeline by AstraZeneca Plc, H2 2015
Recurrent Malignant Glioma - Pipeline by Eisai Co., Ltd., H2 2015
Recurrent Malignant Glioma - Pipeline by MediGene AG, H2 2015
Recurrent Malignant Glioma - Pipeline by Tiziana Life Sciences Plc, H2 2015
Recurrent Malignant Glioma - Pipeline by ZIOPHARM Oncology, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Recurrent Malignant Glioma Therapeutics - Recent Pipeline Updates, H2 2015
Recurrent Malignant Glioma - Dormant Projects, H2 2015
Recurrent Malignant Glioma - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Recurrent Malignant Glioma, H2 2015 7
Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Top 10 Targets, H2 2015 21
Number of Products by Stage and Top 10 Targets, H2 2015 21
Number of Products by Top 10 Mechanism of Actions, H2 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 23
Number of Products by Top 10 Routes of Administration, H2 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 25
Number of Products by Top 10 Molecule Types, H2 2015 27
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report